Imatinib (which targets Bcr-Abl, c-kit, and PDGFR (Morin, 2000)), tyrphostin AG 1296 (which inhibits c-kit and PDGFR (Kovalenko et al, 1994)) and indolinones SU 5416 and SU6597 (inhibitors of c-kit and related kinases (Krystal et al, 2001)) reduce SCLC proliferation in vitro (Krystal et al, 1997, 2000, 2001; Wang et al, 2000; Kijima et al, 2002). Here, KIT is linked to small cell lung carcinoma.